Article Text

Download PDFPDF
Explaining the social gradient in smoking cessation: it’s not in the trying, but in the succeeding
  1. D Kotz1,
  2. R West2
  1. 1
    Department of General Practice, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Centre, Maastricht, The Netherlands
  2. 2
    Cancer Research UK Health Behaviour Unit, Department of Epidemiology and Public Health, University College London, London, UK
  1. Dr Robert West, Cancer Research UK Health Behaviour Unit, Department of Epidemiology and Public Health, University College London, London, UK; robert.west{at}ucl.ac.uk

Footnotes

  • Competing interests: RW undertakes research and consultancy for, and has received travel expenses and hospitality from, companies that develop and market smoking cessation medications. He has a share on a patent for a novel nicotine delivery device.

  • Funding: The Smoking Toolkit Study is funded by Cancer Research UK, Pfizer, J&J and GlaxoSmithKline. DK is the recipient of a European Respiratory Society Fellowship (Number 351).

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: RW undertakes research and consultancy for, and has received travel expenses and hospitality from, companies that develop and market smoking cessation medications. He has a share on a patent for a novel nicotine delivery device.

  • Funding: The Smoking Toolkit Study is funded by Cancer Research UK, Pfizer, J&J and GlaxoSmithKline. DK is the recipient of a European Respiratory Society Fellowship (Number 351).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.